Parcourir Faculté de pharmacie – Travaux et publications par auteur·e "So, Derek Y. F."
Voici les éléments 1-3 de 3
-
Head‐to‐Head comparison of consensus‐recommended platelet function tests to assess P2Y12 Inhibition : insights for multi‐center trials
Bélanger, Jean‐Christophe; Bandeira Ferreira, Fabio Luiz; Welman, Mélanie; Boulahya, Rahma; Tanguay, Jean‐François; So, Derek Y. F.; Lordkipanidzé, Marie (MDPI, 2020)The vasodilator‐associated stimulated phosphoprotein (VASP) phosphorylation level is a highly specific method to assess P2Y12 receptor inhibition. Traditionally, VASP phosphorylation is analyzed by flow cytometry, which is laborious and restricted ... -
Implications of the antiplatelet therapy gap left with discontinuation of prasugrel in Canada
Lordkipanidzé, Marie; Marquis-Gravel, Guillaume; Tanguay, Jean-Francois; Mehta, Shamir R.; So, Derek Y. F. (Elsevier, 2020-12-16)Background The current Canadian Cardiovascular Society antiplatelet therapy guidelines recommend the use of ticagrelor or prasugrel over clopidogrel as first-line platelet P2Y12 receptor antagonists for treatment of moderate- to high-risk acute coronary ... -
Platelet quiescence in patients with acute coronary syndrome undergoing coronary artery bypass graft surgery
Sarathy, Kiran; Wells, George A.; Singh, Kuljit; Couture, Etienne; Chong, Aun-Yeong; Rubens, Fraser; Lordkipanidzé, Marie; Tanguay, Jean-Francois; So, Derek Y. F. (Wiley, 2021)BACKGROUND: The optimal antiplatelet strategy for patients with acute coronary syndromes who require coronary artery bypass surgery remains unclear. While a more potent antiplatelet regimen will predispose to perioperative bleeding, it is hypothesized ...